DNA Vaccination by Electroporation and Boosting with Recombinant Proteins Enhances the Efficacy of DNA Vaccines for Schistosomiasis Japonica

Yang Dai, Yinchang Zhu, Donald A. Harn, Xiaoting Wang, Jianxia Tang, Song Zhao, Fei Lu, and Xiaohong Guan

Jiangsu Institute of Parasitic Diseases, Key Laboratory on Technology for Parasitic Disease Prevention and Control, Ministry of Health, Jiangsu Provincial Key Laboratory on Molecular Biology of Parasites, and Jiangsu Provincial Key Subject on Parasitic Diseases, Wuxi 214064, China; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; and Key Laboratory of Antibody Technique, Ministry of Health, Nanjing Medical University, Nanjing 210029, China

Received 7 June 2009/Returned for modification 2 September 2009/Accepted 29 September 2009

Schistosomiasis japonica is an endemic, zoonotic disease of major public health importance in China. Control programs combining chemotherapy and snail killing have not been able to block transmission of infection in lakes and marsh regions. Vaccination is needed as a complementary approach to the ongoing control programs. In the present study, we wanted to determine if the efficacies of DNA vaccines encoding the 23-kDa tetraspanin membrane protein (SjC23), triose phosphate isomerase (SjCTPI), and sixfold-repeated genes of the complementarity determining region 3 (CDR3) in the H chain of NP30 could be enhanced by boosting via electroporation in vivo and/or with cocktail protein vaccines. Mice vaccinated with cocktail DNA vaccines showed a significant worm reduction of 32.88% (P < 0.01) and egg reduction of 36.20% (P < 0.01). Vaccine efficacy was enhanced when animals were boosted with cocktail protein vaccines; adult worm and liver egg burdens were reduced 45.35% and 48.54%, respectively. Nearly identical results were obtained in mice boosted by electroporation in vivo, with adult worm and egg burdens reduced by 45.00% and 50.88%, respectively. The addition of a protein vaccine boost to this regimen further elevated efficacy to approximately 60% for adult worm burden and greater than 60% for liver egg reduction. The levels of interleukin-2, gamma interferon, and the ratios of immunoglobulin G2a (IgG2a)/IgG1 clearly showed that cocktail DNA vaccines induced CD4+ Th1-type responses. Boosting via either electroporation or with recombinant proteins significantly increased associated immune responses over those seen in mice vaccinated solely with DNA vaccines. Thus, schistosome DNA vaccine efficacy was significantly enhanced via boosting by electroporation in vivo and/or cocktail protein vaccines.

These results demonstrate the potential of DNA vaccination as a complementary approach to the control of schistosomiasis. Several types of vaccines have been developed and tested against Schistosoma japonicum infection (36). These vaccines include DNA, recombinant protein, synthetic peptide, and multivalent vaccines. Several schistosomiasis japonica vaccine candidates have been tested in small and large animals (pigs and water buffalo), including the 23-kDa tetraspanin membrane protein (SjC23), triose phosphate isomerase (TPI), glutathione S-transferase (GST), paramyosin, fatty acid binding protein (FABP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and gynecophoral canal protein (GCP) (36). Each of these vaccines induces partial protection against challenge infection as measured by reduction in total worm burdens: 26.90% to 58.60% for SjC23, 27.90% to 51.20% for TPI, 37.19% to 44.44% for GST, 35.00% to 41.10% for paramyosin, 33.80% for FABP, and 32.40% for GCP (5, 36, 38, 40). Only two vaccines approached 50% efficacy, SjC23 and SjCTPI (5, 38).

DNA vaccination was introduced in 1990 with a study that demonstrated the induction of protein expression upon direct intramuscular injection of plasmid DNA into myocytes (32). The advantages of DNA vaccines over traditional, attenuated, or subunit vaccines are the low cost of production, thermal...
stability, and their ability to induce a wide variety of long-lived cellular and humoral immune responses. In our laboratory, the coding regions for *Schistosoma japonicum* (Chinese strain) 23-kDa membrane protein (SjC23) and triose phosphate isomerase (SjCTPI) were cloned into eukaryotic expression plasmid pcDNA3.1 as a DNA vaccine vector. Several different groups have shown that each of these DNA vaccines induces partial protection in animals, with worm reduction rates ranging from 20% to 58.6%, depending on the animal species challenged and the group performing the study (5, 37, 38, 40, 41).

Cocktail vaccines that include more than one vaccine antigen have been reported to induce higher levels of efficacy than univalent vaccines (13). For example, mice vaccinated with a cocktail DNA vaccine against *Toxoplasma gondii* produced high levels of antiparasite antibody, coincident with lymphocyte proliferation and production of gamma interferon (IFN-γ) following challenge with the parasite (14). Unlike *Toxoplasma*, schistosomes are large, multicellular organisms that undergo several different developmental stages as they mature to egg-laying adult worms in the mammalian host. Therefore, utilization of a vaccine that incorporates multiple schistosome antigens might be capable of inducing immune responses against multiple stages of the parasite, providing a longer time window to harm and/or kill developing worms. In this respect, we previously demonstrated that vaccination with a DNA vaccine that combined pcDNA3.1-SjC23 and pcDNA3.1-SjCTPI plasmids provided greater efficacy than that in animals vaccinated with either single-DNA vaccine. Worm and egg burdens were reduced 41.5% and 61.4% in animals vaccinated with both plasmid DNA vaccines compared to 28.1% and 37.9% for animals vaccinated with pcDNA3.1-SjC23 and 29.1% and 44.2% for animals vaccinated with pcDNA3.1-SjCTPI (39). Thus, combination DNA vaccines are a valid approach for enhancing vaccine efficacy against *Schistosoma japonicum*.

In addition to using cocktail DNA vaccines, studies suggest that prime-boost regimens enhance vaccine efficacy over that seen when only DNA is administered. Prime-boost regimens prime recipients with DNA vaccines and then boost with recombinant proteins or subunit vaccines (20, 23). This approach makes sense, as DNA vaccines consistently drive induction of strong cellular immune responses, while subunit protein vaccines elicit strong humoral responses. Prime-boost vaccine strategies have been successfully applied to many different types of diseases, including AIDS, tuberculosis, and malaria (7, 8, 28). In an earlier study we examined the potential of prime-boost vaccine regimens. We found that mice primed with pcDNA3.1-SjC23 and then boosted with SjC23 recombinant protein had worm and egg numbers reduced by 36.9% and 30.7%, respectively, which was significantly higher than the 26.9% worm and 22.2% egg reductions seen in mice primed and boosted with pcDNA3.1-SjC23. In addition, SjC23-specific antibody responses were higher in the prime-boost group, suggesting that prime-boost regimens had superior efficacy and enhanced immunogenicity compared with DNA-only immunization (24).

Results from several trials of DNA vaccines against *Schistosoma japonicum* have reported worm reduction rates of 27 to 52%, with only two vaccines achieving >50% efficacy. The overall lower efficacy of DNA vaccines may be partially due to insufficient uptake of DNA plasmid by muscle cells, resulting in poor immune responses to vaccine antigens. In this regard, in vivo electrophoresis, electropermeabilization, or electroporation of plasmid DNA has resulted in increased DNA uptake and subsequently enhanced protein expression in treated muscle cells (1, 16). For influenza virus vaccines, when mice were immunized with a plasmid DNA vaccine by electroporation, they subsequently exhibited 100% protection against lethal challenge with H5N1 avian influenza virus, completely blocking virus replication in the lungs (34). In addition, delivery of DNA vaccines by electroporation has been shown to elevate DNA vaccine efficacy over conventional delivery of DNA vaccines for tumors, malaria, and hepatitis (2, 6, 30).

In the present study, we prepared cocktail DNA vaccines by mixing pcDNA3.1-SjC23, pcDNA3.1-SjCTPI, and pcDNA3.1-(CDR3)α, and we also prepared cocktail recombinant protein vaccines consisting of SjC23, SjCTPI, and NP30 and then compared the protective efficacies of these “cocktail” vaccines delivered as conventional DNA/DNA, DNA/electroporation, DNA/recombinant protein, and DNA/electroporation/recombinant protein combinations against *Schistosoma japonicum* challenge infection in BALB/c mice.

### MATERIALS AND METHODS

#### Parasites and animals.
Cercariae were collected from *S. japonicum* (Chinese strain)-infected *Oncomelania hupensis* obtained from the Jiangsu Institute of Parasitic Diseases. Female BALB/c mice, 4 to 5 weeks of age, were purchased from Shanghai SLAC Laboratory Animal Co. Ltd. and used for vaccine trials according to the guidelines of the Animal Research Advisory Committee of the institute.

#### Preparation of cocktail DNA vaccines.
The sixfold-repeated genes of the complementarity-determining region 3 (CDR3) in the heavy (H) chain of NP30 were previously cloned into pcDNA3.1 (29). The genes of pcDNA3.1-SjC23, pcDNA3.1-SjCTPI, and pcDNA3.1-(CDR3)α were purified using Mega plasmid DNA kits (Qiagen, Germany) and diluted into sterile saline solution to a final concentration of 1.5 mg/ml. The cocktail DNA vaccines used for immunization were produced by mixing pcDNA3.1-SjC23, pcDNA3.1-SjCTPI, and pcDNA3.1-(CDR3)α, at equal volumes. The vector plasmid pcDNA3.1 was used as a negative control.

#### Preparation of cocktail protein vaccines.
The genes of SjC23-HD (large hydrophilic domain) and SjCTPI were subcloned into plasmid pGEX-5X-1. The recombinant plasmid was transformed into Escherichia coli BL21(DE3) followed by expression of the protein when induced by isopropyl-β-D-thiogalactoside. The recombinant proteins were purified using the recombinant plasmid DNA vaccine efficacy over conventional delivery of DNA vaccines for tumors, malaria, and hepatitis (2, 6, 30).

#### ELECTROPORATION IN VIVO
Electroporation in vivo was carried out according to the method described by Aihara and Miyazaki (1). A pair of electrode needles 5 mm apart was inserted into the muscle to cover the DNA injection sites, and electric pulses were delivered using an electric pulse generator (programmed control stimulator YC-2; Chengdu Instrument Factory, Chengdu, China). Four pulses of 100 V each were delivered to each injection site at the rate of one pulse per second, with each pulse lasting for 40 ms. Then, four pulses of the opposite polarity were applied.

#### IMMUNIZATION AND CHALLENGE INFECTION.
(i) **Experiment 1.** A total of 126 female 4- to 5-week-old BALB/c mice were divided randomly into nine groups (A to I) and vaccinated intramuscularly with 100-μl volumes at weeks 0, 3, and 6 for experiment 1. Groups boosted with recombinant proteins were injected at week 9 subcutaneously with recombinant protein solutions mixed with complete Freund’s adjuvant. Group A, the injection control, was immunized with saline solution; group B, the pcDNA3.1 control, was immunized with pcDNA3.1; group C, the pcDNA3.1 control, was then boosted with cocktail protein vaccines; group
D received cocktail DNA vaccines; group E received cocktail DNA vaccines and then was boosted with recombinant protein vaccines; group F received pcDNA3.1/EP control injected intramuscularly (EP); group G received pcDNA3.1 control with EP and then was boosted with recombinant protein vaccines; group H received cocktail DNA vaccines with EP; group I received cocktail DNA with EP and then was boosted with recombinant protein vaccines; group j received pcDNA3.1-SjCTPI plasmid DNA; group h received pcDNA3.1-SjCTPI with EP.

For both experiments I and II, mice were challenged with 40 ± 5 cercariae of *S. japonicum* 4 weeks after the final DNA immunization or 2 weeks after the protein boost, by abdominal skin penetration.

**RESULTS**

**Determination of protective efficacy against challenge infection.** Efficacies of the different vaccination regimens were calculated as differences in adult male and female worm burdens as well as reductions in liver egg burdens 42 days postchallenge. The results of the two experiments are presented in Tables 1 and 2. In experiment I (Table 1), mice inoculated intramuscularly with cocktail DNA vaccines (group D) showed a significant worm reduction of 32.88% (*P* < 0.01) and egg reduction of 36.20% (*P* < 0.01) compared to mice injected with saline or pcDNA3.1 control (groups A and B). Reductions in worm and egg burdens were enhanced when these groups were boosted with cocktail protein vaccines (group E), with adult worm and egg reduction rates of 45.35% and 48.54%, respectively. Interestingly, nearly identical results were obtained in mice boosted with cocktail DNA vaccines administered by electroporation (group H), with adult worm and egg burdens reduced by 45.00% and 50.88%, respectively. There was a significant difference in both worm and egg reduction rates between group D and group E (*P* < 0.05) and between group D and group H (*P* < 0.05). A further significant increase in vaccine efficacy was seen when we employed each of the three vaccination methods on the same group of mice (group I). Mice immunized with cocktail DNA vaccines, boosted with cocktail DNA vaccines by electroporation, and then given a final boost with cocktail protein vaccines had adult worm and liver egg burdens reduced by 57.09% (*P* < 0.01) and 59.26% (*P* < 0.01), respectively, compared to control groups A and B. There were significant differences in both worm and egg burdens between group I and group H (*P* < 0.05) and between group I and group E (*P* < 0.05).

**Similar results were obtained in experiment II (Table 2). We**

**TABLE 1. Protective efficacies of different vaccination regimens against Schistosoma japonicum challenge infection (experiment I)**

| Group                                      | No. of mice | Total no. of worms (%) | % Worm reduction (mean ± SD) | % Egg reduction (mean ± SD) |
|--------------------------------------------|-------------|------------------------|-------------------------------|-----------------------------|
| A (blank control)                          | 11          | 25.82 ± 3.25           | 62.001 ± 9.814               |
| B (pcDNA3.1)                               | 10          | 25.40 ± 2.46           | 61.761 ± 13.787              |
| C (pcDNA3.1 and cocktail protein vaccines)  | 12          | 21.25 ± 3.12           | 17.70                        |
| D (cocktail DNA vaccines)                  | 9           | 17.33 ± 2.74           | 32.88                        |
| E (cocktail DNA and protein vaccines)       | 9           | 14.11 ± 3.55           | 45.35                        |
| F (pcDNA3.1 with EP)                       | 10          | 25.30 ± 3.80           | 58.272 ± 11.680              |
| G (pcDNA3.1 with EP and cocktail protein vaccines) | 13        | 21.15 ± 3.44           | 18.09                        |
| H (cocktail DNA vaccines with EP)           | 10          | 14.20 ± 3.12           | 45.00                        |
| I (cocktail DNA with EP and protein vaccines) | 12         | 11.08 ± 3.42           | 57.09                        |

*Values for worm and egg numbers are means ± standard deviations. Worm and egg reduction rates of each vaccine group were compared to group A (blank control). Statistically significant differences in egg reduction rates were seen in group E versus group C (*P* < 0.01) or group D (*P* < 0.05). Worm and egg burdens were significantly reduced in group H versus group D (*P* < 0.05); also, worm and egg burdens were significantly reduced in group I compared to group E (*P* < 0.05) or group H (*P* < 0.05).

Values for worm and egg burdens and antibody levels were compared using a one-way analysis of variance, and a *P* value of <0.05 was considered statistically significant.
observed that adult worm and liver egg burdens were significantly reduced in mice immunized with cocktail DNA vaccines (group e), 41.47% and 52.83%, respectively, or univalent DNA vaccine pcDNA3.1-SjCTPI (group h), 42.37% and 42.75%, respectively, followed by electroporation in vivo, compared to group c (32.54% and 44.06%) and group g (27.23% and 27.25%).

Determination of vaccination-induced antigen-specific antibodies. To evaluate vaccine-specific antibody responses, serum was collected from each mouse and analyzed by enzyme-linked immunosorbent assay (ELISA) for antibody titers against the mixture of vaccine antigens (see Materials and Methods).

The levels of total IgG and the IgG isotypic responses of mice in the various groups from the two experiments are shown in Table 2. The detection of the IgG, IgG1, and IgG2a levels was repeated in the two experiments and showed similar results.

In experiment I (Fig. 1), mice immunized with cocktail DNA vaccines and/or cocktail protein vaccines produced vaccine antigen-specific IgG, while sera from control groups did not. Interestingly, group E, vaccinated using cocktail DNA priming and protein boosting, had a significantly higher antibody response ($A_{450}$, 2.63) than group D, which was vaccinated solely with cocktail DNA vaccines ($A_{450}$, 1.37). Similarly, there was a significantly elevated vaccine specific antibody response in group H mice vaccinated with cocktail DNA vaccines followed by electroporation in vivo ($A_{450}$, 2.04) compared to mice solely vaccinated with cocktail DNA vaccines (group D).

Mice immunized with cocktail DNA vaccines and then boosted with cocktail protein vaccines produced vaccine-specific IgG1 and IgG2a antibodies, with ratios of IgG2a/IgG1 of 0.525, 1.829, and 0.712 in groups C, D, and E and 0.394, 3.518, and 0.914 in groups G, H, and I, respectively. Levels of total IgG and IgG1 were increased significantly compared to control

**Table 2.** Protective efficacies of different vaccination regimens against *Schistosoma japonicum* infection (experiment II)*

| Group     | No. of mice | Total no. of worms | % Worm reduction | No. of female worms | % Female-worm reduction | No. of eggs in liver | % Egg reduction |
|-----------|-------------|--------------------|------------------|---------------------|------------------------|---------------------|-----------------|
| a (pcDNA3.1) | 10          | 22.40 ± 2.59       | 10.10 ± 3.38     | 64,849 ± 11,452    | 20.62                  |
| b (pcDNA3.1 with EP and cocktail protein vaccines) | 11          | 19.09 ± 3.54       | 7.00 ± 2.44       | 51,479 ± 9,833       | 57.57                  |
| c (cocktail DNA vaccines) | 9           | 15.11 ± 2.09       | 32.54            | 36,275 ± 13,069     | 44.06                  |
| d (cocktail DNA and protein vaccines) | 9           | 12.56 ± 1.94       | 5.33 ± 3.35      | 25,713 ± 8,181       | 53.80                  |
| e (cocktail DNA vaccine with EP) | 9           | 13.11 ± 2.71       | 4.67 ± 1.73      | 30,592 ± 3,379       | 52.83                  |
| f (cocktail DNA with EP and protein vaccines) | 10          | 9.10 ± 3.21        | 2.59 ± 1.23      | 21,081 ± 11,856      | 67.49                  |
| g (TPI) | 10          | 16.30 ± 2.36       | 27.23            | 47,180 ± 10,735      | 27.25                  |
| h (TPI with EP) | 11          | 12.91 ± 2.59       | 42.37            | 37,127 ± 10,953      | 42.75                  |

*a Values for worm and egg counts are means ± standard deviations. Adult worm and liver egg reduction rates were calculated for each group in comparison to group a. Statistically significant differences in adult worm and liver egg burdens were seen for the following comparisons: between group d and group b ($P < 0.01$); between group e and group c ($P < 0.05$); between group h and group g (TPI) ($P < 0.01$); and between group f and group d ($P < 0.05$).
groups when cocktail proteins were used for boosters. Further, the levels of IgG2a were significantly increased compared to the group primed with cocktail DNA vaccines and then boosted by electroporation in vivo.

In experiment II (Fig. 2), similar tendencies were observed in terms of IgG2a/IgG1 ratios. Group-specific ratios were as follows: group b, 0.373; group c, 2.152; group d, 0.581; group e, 2.669; group f, 0.659; group g, 1.943; group h, 2.599. Compared to the nonelectroporation group, there were significant elevations of IgG levels in the group primed with cocktail DNA vaccines followed by boosting via electroporation. We also observed elevations in vaccine-specific IgG levels in mice boosted with cocktail protein vaccines, compared to boosting with cocktail DNA vaccines.

**Vaccine-specific cytokine production induced by various vaccination regimens.** In addition to measuring antigen-specific antibody responses, we also assayed for production of IL-2, IFN-γ, and IL-4 in response to stimulation with SEA or ConA. Splenocytes were harvested as described in Materials and Methods and then pulsed with medium (blank), ConA, or SEA for 72 h and supernatants collected. Levels of IL-4 in all groups from both trials were less than 10 pg/ml (the minimum limit of detection using this kit is 10 pg/ml). This is consistent with earlier studies with TPI and the 23-kDa integral membrane protein candidate vaccine antigens driving Th1-type but not Th2-type immune responses (9, 10). Levels of IL-2 and IFN-γ for each of the two experiments are presented in Tables 3 and 4, respectively.

In experiment I levels of IL-2 in response to ConA or SEA in each of the three control groups (A, B, and F) were undetectable or minimal (Table 3). Similar to the results for vaccine efficacy, the highest levels of IL-2 were seen in groups H and I, the groups boosted via electroporation or with electroporation followed by a final boost with cocktail recombinant vaccine proteins (group I), with the highest levels of IL-2 detected from splenocytes of group I animals. Results for IFN-γ followed a similar pattern to those detected for IL-2, with the three control groups (A, B, and F) having negligible levels of IFN-γ production and groups H and I having the highest levels of IFN-γ production. Interestingly, levels of IFN-γ were also significantly elevated in groups D (cocktail DNA vaccines) and E (cocktail DNA vaccines and protein cocktail boost). The levels of IL-2 and IFN-γ were highest in the groups that received a vaccine boost via electroporation.

Experiment II compared the three optimal vaccination regimens determined in the trials in experiment I, as well as two groups, g and h, for which SjCTPI DNA was the only vaccine antigen (Table 4). Levels of IL-2 from SEA-stimulated splenocytes were highest in group f, the group with the highest level of protective efficacy. Group f received cocktail DNA vaccines as a prime, followed by cocktail DNA vaccines electroporated with a final boost of cocktail protein vaccines. Interestingly, groups g and h, which both utilized only SjCTPI DNA vaccine, elicited fairly high levels of IL-2. Consistent with data throughout this study, in group f in this experiment (group I in experiment I) the highest levels of IFN-γ were induced. Splenocytes from mice vaccinated only with SjCTPI (g and h) had elevated levels of both IL-2 and IFN-γ. The levels of IFN-γ for these two groups (g and h) were not as significantly elevated as the levels of IL-2.

---

**TABLE 3. Boosting with cocktail DNA vaccines by electroporation or with cocktail protein vaccines leads to enhanced production of IL-2 and IFN-γ (experiment I)**

| Group | IL-2 (pg/ml)<sup>a</sup> | IFN-γ (pg/ml)<sup>a</sup> |
|-------|----------------|-------------------|
|       | Blank | ConA | SEA | Blank | ConA | SEA |
| A     | <10   | 10.18 | 10.01 | <10   | 10.18 | 10.01 |
| B     | <10   | <10   | 11.11 | <10   | <10   | 17.58 |
| C     | <10   | 18.50 | 24.90 | <10   | 19.54 | 36.70 |
| D     | <10   | 20.90 | 59.21 | <10   | 120.72 | 492.31 |
| E     | <10   | 23.97 | 68.02 | <10   | 123.86 | 503.90 |
| F     | <10   | <10   | <10   | <10   | 11.95 | 39.55 |
| G     | <10   | 21.46 | 52.94 | <10   | 27.58 | 83.15 |
| H     | <10   | 39.15 | 79.28 | <10   | 300.79 | 625.55 |
| I     | <10   | 43.92 | 112.02 | <10   | 97.05 | 664.23 |

<sup>a</sup> Data are average values of readings from triplicate wells for each group.

**TABLE 4. Boosting by electroporation or with cocktail protein vaccines leads to enhanced production of IL-2 and IFN-γ (experiment II)**

| Group | IL-2 (pg/ml)<sup>a</sup> | IFN-γ (pg/ml)<sup>a</sup> |
|-------|----------------|-------------------|
|       | Blank | ConA | SEA | Blank | ConA | SEA |
| a     | <10   | 37.54 | 13.11 | <10   | 38.97 | 26.56 |
| b     | <10   | 91.99 | 111.48 | <10   | 35.35 | 197.98 |
| c     | <10   | 45.39 | 234.68 | <10   | 49.32 | 439.27 |
| d     | <10   | 75.33 | 270.74 | <10   | 75.33 | 546.32 |
| e     | <10   | 89.65 | 254.71 | <10   | 96.71 | 896.43 |
| f     | <10   | 43.17 | 431.73 | <10   | 92.67 | 1,398.04 |
| g     | <10   | 31.72 | 110.30 | <10   | 65.04 | 265.04 |
| h     | <10   | 74.32 | 231.28 | <10   | 83.43 | 318.23 |

<sup>a</sup> Data are average values of readings from triplicate wells for each group.
DISCUSSION

Schistosomiasis is an infectious disease that is widespread in tropical and subtropical countries. China is one of the countries where schistosomiasis is endemic. Current schistosomiasis control strategies in China are based on chemotherapeutic treatment of infected individuals and eradication of the snail intermediate hosts (25). In the lakes and marsh regions of China, seasonal transmission means that a large percentage of individuals residing in these areas will be reinfected on an annual or frequent basis, requiring constant monitoring of infection and drug treatment with praziquantel. Annual administration of praziquantel, the drug of choice for more than 30 years, provides an opportunity for schistosomes to become resistant to this drug. In other countries where praziquantel is administered in mass chemotherapy programs, resistance has been reported (3, 12). Thus, the development of alternative, long-term control measures, such as vaccines, is required. Control of schistosomiasis in the lakes and marsh regions of China as well as other Southeast Asian countries and in Saharan Africa will require development of interventions that reduce the numbers of infecting parasites such that the numbers of egg-laying adult parasites are significantly reduced, leading to reductions in the numbers of eggs shed into the environment and reducing transmission of the disease.

The use of partially protective vaccines administered in conjunction with praziquantel treatment has been considered an ideal control measure for some time. To date, a number of candidate vaccines have been tested in various animal models of schistosomiasis japonica, including several different DNA vaccines (SjFABP, SjGCP, SjGST, SjC23, and SjCTPI). Each of these DNA vaccines provided partial protection against Schistosoma japonicum infection in mice (36). The purpose of this study was to determine if administration of partially protective DNA vaccines via different regimens would significantly elevate vaccine efficacy over that previously reported. Schistosoma japonicum is a complex helminth parasite with multiple life cycle stages in the mammalian definitive host. Additionally, the parasite has a complex outer membrane structure which helps parasites evade immune system recognition. Therefore, for this study, we decided to vaccinate mice with cocktail vaccines that allowed us to target parasite membranes (SjC23), a glycolytic enzyme (SjCTPI), and a gut-associated antigen (CDR3). Vaccination with cocktail DNA vaccines provided a 32.88% worm reduction rate and 36.20% egg reduction rate, which was slightly higher than efficacy levels for univalent DNA vaccines delivered by injection (P < 0.05). Experiment II provided nearly identical results, showing significantly increased vaccine efficacy when electroporation was used to deliver the cocktail DNA vaccine boost, rather than intramuscular injection. Examination of splenocyte responses to ConA or parasite antigens demonstrated that mice vaccinated via the regimen of cocktail DNA vaccines with EP produced higher concentrations of IL-2 and IFN-γ than cells from mice immunized with DNA vaccines delivered by injection. Thus, administration of DNA vaccines by electroporation significantly enhances vaccine efficacy and immunogenicity. The reason for this may be electroporation in vivo is a more efficient way to get DNA into muscle cells, which would augment expression of vaccine antigens, providing greater immune system stimulation (27). Another possibility is that the application of an electric field directly in the tissue results in an inflammatory response that aids priming of immune responses against DNA-encoded antigens (30). The electroporation protocol that we employed here has been successfully utilized for DNA vaccines for several different diseases (19).

Prime-boost strategies were developed to improve overall vaccine efficacy following priming with plasmid DNA. Prime-boost strategies deliver DNA vaccines for the priming immunization and then boost with proteins, peptides, or live attenuated viruses (22). Results for this immunization strategy have been highly encouraging in both augmenting and modulating vaccine-induced immunity against many diseases. In the present study, we primed with cocktail DNA vaccines against Schistosoma japonicum and then boosted with cocktail protein vaccines. In this study we found that mice vaccinated via the prime-boost regimen had enhanced protection against challenge infection compared to mice vaccinated via the DNA-DNA regimen. Adult worms and liver egg burdens were reduced 32.88% and 36.20%, respectively, in DNA-DNA-treated mice, compared to 45.35% and 48.54%, respectively, in prime-boost-vaccinated mice (experiment I, with similar results in experiment II).

In addition to increasing vaccine efficacy, vaccination via prime-boost significantly increased vaccine-specific antibody responses over those seen in mice solely vaccinated with plasmid DNA vaccines. The positive impact of protein boosting on vaccine-specific antibody responses has been demonstrated previously (7, 8, 20, 23, 28). These enhanced vaccine responses are likely due to increased antigen presentation. In contrast to proteins expressed in the cytosol following DNA injection, injected proteins are endocytosed and presented on major histocompatibility complex class II molecules, facilitating humoral responses (15). In addition, antibody maturation through increased avidity may also play a role in mice immunized by DNA priming followed by protein boosting. Interestingly, protein boosting had a greater effect on vaccine-specific antibody production in animals whose first boost was via electroporation compared to the groups of mice that received cocktail DNA vaccines by injection in both experiments. Taken together with the efficacy results, electroporation has a beneficial impact on enhancing vaccine-specific immune responses. As mentioned earlier, one possible mechanism is that electroporation-mediated tissue damage may act by recruiting mononuclear cells to the site of antigen expression, as observed by Gronevik et al. (10, 17).
Several groups have suggested that cell-mediated immunity involving IFN-γ-activated cells may be one mechanism of protective immunity in the mouse schistosome challenge model (4, 9, 21). In this regard, in vitro studies have demonstrated that schistosomula, the presumed target stage for both SjC23 and SjCTPI vaccines, were killed by macrophages or endothelial cells activated via combinations of cytokines, including IFN-γ and IL-12 (33). Therefore, Th1-type immune responses seem to be important in the induction of vaccine-induced resistance to schistosomiasis in mice. In the present study, the levels of IL-2 and IFN-γ and the ratios of IgG2a/IgG1 clearly showed that vaccination with these DNA vaccines induced CD4+ Th1-type responses.

While boosting via electroporation or with recombinant proteins significantly increased vaccine efficacy and associated immune responses over those seen in mice vaccinated solely with cocktail DNA vaccines, the vaccine regimen that combined each of these approaches induced the highest levels of protective efficacy, inducing 60% or greater reductions in adult worm and liver egg burdens. The results of these trials show that there are better ways to deliver schistosome vaccines in mice and that these methods should rapidly be attempted in large animals, such as water buffalo, to determine if these vaccination regimens approach are effective in large animals which have been shown to play large roles in the transmission of schistosomiasis.

With regard to schistosomiasis in humans, serious symptoms of schistosomiasis generally appear in people who harbor large numbers of parasites, and thus a vaccine able to effectively reduce a patient’s worm burden by 50% or more could dramatically reduce the number of severe cases of the disease, decreasing morbidity. Furthermore, as with vaccination of water buffalo, a 50% efficacious vaccine for human schistosomiasis would decrease transmission of the disease (18). In this study, two large experiments were carried out that compared multiple vaccination parameters. We found that vaccination with cocktail plasmid DNA vaccines that included a boost administered by electroporation increased vaccine efficacy by approximately 60% for adult worm burden reduction and greater than 60% for liver egg reduction. Employment of either vaccine regimen in water buffalo alone, combined with praziquantel treatment, should result in significant decreases in transmission of the disease in the lakes and marsh regions, based on mathematical models of transmission in these regions of China (31). Importantly, if these vaccines were to be utilized in humans as well as bovines, then one would expect to see a dramatic drop in transmission of schistosomiasis as well as a reduction in infection prevalence and intensity. We believe that if either of these two improved vaccination regimens are shown to augment vaccine efficacy in water buffalo, and these findings are taken together with previous work by our groups, a standard vaccination protocol for schistosomiasis in China and eventually other regions of the world will be developed.

**ACKNOWLEDGMENTS**

This investigation received financial support from the UNDP/World Bank/WHO special program for Research and Training in Tropical Disease (991051) and partial support from Jiangsu Provincial Department of Health (H99118) and NIH grant AI068109-01A1 (D. Harn). We thank Akram Da’dara for his comments during preparation of the manuscript.

**REFERENCES**

1. Aihara, H., and J. Miyazaki. 1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:867–870.
2. Buchan, S., E. Gronevik, I. Mathiesen, C. A. King, F. K. Stevenson, and J. Rice. 2005. Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 174:6292–6298.
3. Chitsulo, L., D. Engels, A. Montresor, and L. Savioi. 2000. The global status of schistosomiasis and its control. Acta Trop. 77:41–51.
4. Cook, R. M., C. Carvalho-Queiroz, G. Wilding, and P. T. LoVerde. 2004. Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the schistosome worm stage. Infect. Immun. 72:6112–6124.
5. Da’dara, A. A., Y. S. Li, T. Xiong, J. Zhou, G. M. Williams, D. P. McManus, Z. Feng, X. L. Yu, D. J. Gray, and D. A. Harn. 2008. DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine 26:3617–3623.
6. Dobano, C., G. Widera, D. Rabussay, and D. L. Doolan. 2007. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine 25:6635–6645.
7. Dunachie, S. J., and A. V. Bill. 2003. Prime-boost strategies for malaria vaccine development. J. Exp. Biol. 206:3771–3779.
8. Ferraz, J. C., E. Stavropoulos, M. Yang, S. Coade, C. Espitia, D. B. Lowrie, M. J. Colston, and R. E. Tascón. 2004. A heterologous DNA priming-Mycobacterium bovis BCG boost strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect. Immun. 72:6945–6950.
9. Fonseca, C. T., C. F. Brito, J. B. Alves, and S. C. Oliveira. 2004. IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine 22:803–810.
10. Gronevik, E., S. Tollefsen, L. L. Sikkeland, T. Haug, T. E. Tjelle, and I. Mathiesen. 2003. DNA transfection of mononuclear cells in muscle tissue. J. Gene Med. 5:909–917.
11. Hao, Y., X. H. Wu, H. Zheng, L. Y. Wang, J. G. Guo, G. Xia, C. Chen, and X. N. Zhou. 2008. Schistosomiasis situation in People’s Republic of China in 2007. J. Schisto. Control 20:401–404. (In Chinese.)
12. Harder, A. 2002. Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol. Res. 88:395–397.
13. Irvine, C., and K. Chaade. 2004. DNA vaccines: designing strategies against parasitic infections. Genet. Vaccines Ther. 2:1–8.
14. Jongert, E., V. Melkebeek, S. De Craeye, J. Dewit, D. Verhelst, and E. Cox. 2008. An enhanced GRA1-GRA7 cocktail DNA vaccine primes anti-Toxoplasma immune responses in pigs. Vaccine 6:1025–1031.
15. Li, Y., L. B., H. Y. Zhang, Y. Zhang, L. Qu, Q. L. Liu, T. E. Tjelle, I. Mathiesen, R. Kjeken, and S. D. Xiong. 2006. DNA electroporation prime and protein boost strategies enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 24:4556–4568.
16. Mathiesen, I. 1999. Electroporation of skeletal muscle enhances gene transfer in vivo. Gene Ther. 6:508–514.
17. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991–1045.
18. McManus, D. P. 2000. A vaccine against Asian schistosomiasis: the story unfolds. Int. J. Parasitol. 30:265–271.
19. Mir, L. M., M. F. Bureau, J. Gehi, R. Rangara, D. Rouy, J. M. Caillaud, P. Delaere, D. Branellec, B. Schwartz, and D. Scherman. 1999. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. USA 96:4262–4267.
20. Newman, M. J. 2002. Heterologous prime-boost vaccination strategies for HIV-1; augmenting cellular immune responses. Curr. Opin. Investig. Drugs 3:357–368.
21. Pancré, V., I. Wołowczuk, S. Guerret, M. C. Copin, A. Delanoye, A. Capron, and C. Auriel. 1994. Protective effect of rS.m2GST-specific T cells in schistosomiasis: role of gamma interferon. Infect. Immun. 62:3723–3730.
22. Ramshaw, L. A., and A. J. Ramsay. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21:63–65.
23. Rasmussen, R. A., R. Hofmann-Lehmann, D. C. Montefiori, P. L. Li, V. Liska, J. Vlasak, T. W. Baba, J. E. Schmitz, M. J. Kuroda, H. L. Robinson, H. M. Michel, S. Lu, S. L. Hu, T. A. Rizvi, and R. M. Ruprecht. 2002. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J. Med. Primatol. 31:40–60.
24. Ren, J. G., Y. C. Zhu, D. A. Harn, C. X. Yu, J. Si, X. R. Yin, Y. S. Liang, M. Xu, and Y. L. Xu. 2002. Protective immunity effects of co-immunization with SjC23 DNA vaccine and protein vaccine. J. Schisto. Control 14:96–101. (In Chinese.)
25. Ross, A. G. P., A. C. Sleigh, Y. Li, G. M. Davis, G. M. Williams, Z. Jiang, Z.
Feng, and D. P. McManus. 2001. Schistosomiasis in the People’s Republic of
China: prospects and challenges for the 21st century. Clin. Microbiol. Rev. 14:270–295.
26. Steinmann, P., J. Keiser, R. Bos, M. Tanner, and J. Utzinger. 2006. Schis-
itosomiasis and water resources development: systematic review, meta-analysis,
and estimates of people at risk. Lancet Infect. Dis. 6:411–425.
27. Tollefsen, S., T. Tjelle, J. Schneider, M. Harboe, H. Wiker, G. Hewinson, K.
Huygen, and I. Mathiesen. 2002. Improved cellular and humoral immune
response against Mycobacterium tuberculosis antigens after intramuscular
DNA immunization combined with muscle electroporation. Vaccine 20:
3370–3378.
28. Wan, S. X., J. Arthos, J. M. Lawrence, D. V. Ryk, I. Mboutjeka, S. Y. Shen,
T. W. Chou, D. C. Montefiori, and S. Lu. 2005. Enhanced immunogenicity of
gp120 protein when combined with recombinant DNA priming to generate
antibodies that neutralize the JR-FL primary isolate of human immuno-
deficiency virus type 1. Virology 79:7933–7957.
29. Wang, X. T., Y. C. Zhu, X. H. Guan, J. Si, S. Zhao, D. A. Harn, X. R. Yin,
Y. S. Liang, W. He, and M. Xu. 2005. Construction of multivalent DNA
vaccine of Schistosoma japonicum and its identification. J. Schisto. Control
17:166–171. (In Chinese.)
30. Widera, G., M. Austin, D. Rabussay, C. Goldbeck, S. W. Barnett, M. C.
Chen, L. Leung, G. R. Otten, K. Thudium, M. J. Selby, and J. B. Ulmer.
2000. Increased DNA vaccine delivery and immunogenicity by electropa-
oration in vivo. J. Immunol. 164:4635–4640.
31. Williams, G. M., A. C. Sleigh, Y. Li, Z. Feng, G. M. Davis, H. Chen, A. G.
Ross, R. Bergquist, and D. P. McManus. 2002. Mathematical modelling of
schistosomiasis japonica: comparison of control strategies in the People’s
Republic of China. Acta Trop. 82:253–262.
32. Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, and
P. L. Felgner. 1990. Direct gene transfer into mouse muscle in vivo. Science
247:1465–1468.
33. Wynn, T. A., D. Jankovic, S. Hiemy, A. W. Cheever, and A. Sher. 1995. IL-12
enhances vaccine-induced immunity to Schistosoma mansoni in mice and
decreases T helper 2 cytokine expression, IgE production, and tissue eosin-
ophilia. J. Immunol. 154:4701–4709.
34. Zhang, Q. Z., X. M. Qin, H. L. Dong, R. Liang, H. X. He, X. Li, B. Y. Jiang,
X. J. Liu, and M. X. Duan. 2005. Efficient protection of H5N1 influenza virus
DNA vaccine delivering by electroporation in mammalian and avian system.
Prog. Biochem. Biophys. 32:726–732.
35. Zheng, J. 2003. Schistosomiasis control and its prospect in China. J. Schisto.
Control 15:1–2. (In Chinese.)
36. Zhou, X., and H. X. Zhuge. 2007. Progress of research on nucleic acid
vaccine against Schistosomiasis japonica. J. Schisto. Control 19:317–320. (In
Chinese.)
37. Zhu, Y. C., J. Ren, D. A. Harn, J. Si, C. X. Yu, M. Xu, and Y. S. Liang. 2003.
Protective immunity induced with 23 kDa membrane protein DNA vaccine of
Schistosoma japonicum Chinese strain in infected C57BL/6 mice. South-
east Asian J. Trop. Med. Public Health 34:697–701.
38. Zhu, Y., J. Ren, A. Da’dara, D. Harn, M. Xu, J. Si, C. X. Yu, Y. S. Liang, P.
Ye, X. R. Yin, W. He, Y. L. Xu, G. Q. Cao, and W. Q. Hua. 2004. The
protective effect of a Schistosoma japonicum Chinese strain 23 kDa plasmid
DNA vaccine in pigs is enhanced with IL-12. Vaccine 23:78–83.
39. Zhu, Y. C., J. G. Ren, J. Si, D. A. Harn, C. X. Yu, Y. S. Liang, X. R. Yin, M.
Xu, and Y. L. Xu. 2002. Protective immunity with co-immunization of SjC23
DNA vaccine and SjCTPI DNA vaccine in Schistosoma japonicum. J.
Schisto. Control 15:134–137. (In Chinese.)
40. Zhu, Y., J. Si, D. A. Harn, M. Xu, J. Ren, C. Yu, Y. S. Liang, X. Yin, W. He,
and G. Cao. 2006. Schistosoma japonicum triose-phosphate isomerase plas-
mid DNA vaccine protects pigs against challenge infection. Parasitology
132:67–71.
41. Zhu, Y., J. Si, D. A. Harn, C. Yu, W. He, W. Q. Hua, X. R. Yin, Y. S. Liang,
M. Xu, and Y. L. Xu. 2002. The protective immunity produced in infected
C57BL/6 mice of a DNA vaccine encoding Schistosoma japonicum chinese
strain triose-phosphate isomerase. Southeast Asian J. Trop. Med. Public
Health 33:207–213.